(R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo
about
Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-leadNew therapeutic targets for mood disordersBipolar disorder: candidate drug targets.Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behaviorThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsPICK1 uncoupling from mGluR7a causes absence-like seizures.Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators.A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo.Glutamatergic modulators: the future of treating mood disorders?G-protein-coupled receptors for neurotransmitter amino acids: C-terminal tails, crowded signalosomes.Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.Effects of diazepam on glutamatergic synaptic transmission in the hippocampal CA1 area of rats with traumatic brain injury.Phenylglycine derivatives as antagonists of group III metabotropic glutamate receptors expressed on neonatal rat primary afferent terminals.Constitutive activity of metabotropic glutamate receptor 7.Novel glutamatergic agents for major depressive disorder and bipolar disorder.Therapeutic potential of metabotropic glutamate receptor modulators.Agonists and antagonists of metabotropic glutamate receptors: anticonvulsants and antiepileptogenic agents?Group III metabotropic glutamate receptors (mGluRs) modulate transmission of gustatory inputs in the brain stem.The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.Targeting glutamatergic signaling for the development of novel therapeutics for mood disordersGlutamate receptors as therapeutic targets for Parkinson's disease.Group III mGlu receptor agonist, ACPT-I, exerts potential neuroprotective effects in vitro and in vivoMetabotropic Glutamate Receptors and Epileptogenesis.Selective mGluR1 antagonist EMQMCM inhibits the kainate-induced excitotoxicity in primary neuronal cultures and in the rat hippocampus.Neuroprotection against hypoxic/hypoglycaemic injury after the insult by the group III metabotropic glutamate receptor agonist (R, S)-4-phosphonophenylglycine.Group I mGluR-induced epileptogenesis: distinct and overlapping roles of mGluR1 and mGluR5 and implications for antiepileptic drug design.
P2860
Q24614930-9366FD9E-DF02-46EB-B0D9-617126DCC3CDQ28743068-2D578409-4F9C-44EC-9BC8-D4694C313172Q28751133-76217A8B-1526-465C-888B-2693AF12B14FQ30414092-00D68425-66E7-46E8-A628-F02994CCA5A6Q30486707-9406848B-F565-4982-B358-E93B0E7DC99BQ30491105-5A915CFF-6DED-4856-8293-6653DB50CA20Q33369679-72A43EFB-6FC4-4BDD-8D8C-B9C0A3F326D6Q34234693-30D30173-E89A-40E6-80D5-CA3EA1DA73AFQ34398007-0E5DBC71-F63C-4D69-9702-A705F0C77443Q34634508-8126CEDA-C137-4CC4-981D-91B6E7FE0324Q34766451-F1798FE7-6F74-490A-89D0-5C7B10E46C69Q34798743-675A02F0-DDA1-42DB-A345-D23B4ECCE7A3Q35045579-56546E1E-2B69-4303-8C67-6DBBA502ADC2Q35604302-2CD97065-5858-431D-AD98-715DEB93A267Q35661119-551040E1-0639-4BC0-B538-F555511AAFFCQ35778704-29AC14D5-B598-41B6-AB0A-5C29059D0EEDQ36499746-DA368CB8-F814-4FC9-8CFF-3351D7B70950Q37265883-5797B31D-FAE3-47A8-83D0-FD43B74A725EQ37387700-311CB703-5313-401C-8A9B-644772314013Q37481603-3CA36A26-A484-44A8-BEDC-4F41DD291090Q37585401-A47F229A-B8BA-4F17-BC41-8581B1995AFCQ39982710-BA95571F-0D34-4E09-9D9F-8C00BB21D29FQ40466434-74C0ABCA-DD59-4443-A3AB-ED42911528C9Q41811282-B7AB729C-FA30-45DA-8744-B8EF3C676093Q41829213-195FAEE3-EF4F-48EF-A35C-89DCF4335419Q42139378-DF185668-A4BB-41F8-8A56-01A60CCBA7B9
P2860
(R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
(R,S)-4-phosphonophenylglycine ...... ve and neuroprotective in vivo
@ast
(R,S)-4-phosphonophenylglycine ...... ve and neuroprotective in vivo
@en
(R,S)-4-phosphonophenylglycine ...... ve and neuroprotective in vivo
@nl
type
label
(R,S)-4-phosphonophenylglycine ...... ve and neuroprotective in vivo
@ast
(R,S)-4-phosphonophenylglycine ...... ve and neuroprotective in vivo
@en
(R,S)-4-phosphonophenylglycine ...... ve and neuroprotective in vivo
@nl
prefLabel
(R,S)-4-phosphonophenylglycine ...... ve and neuroprotective in vivo
@ast
(R,S)-4-phosphonophenylglycine ...... ve and neuroprotective in vivo
@en
(R,S)-4-phosphonophenylglycine ...... ve and neuroprotective in vivo
@nl
P2093
P1476
(R,S)-4-phosphonophenylglycine ...... ve and neuroprotective in vivo
@en
P2093
E C Johnson
F Gasparini
F Nicoletti
G Battaglia
M A Varney
P304
P407
P577
1999-06-01T00:00:00Z